Diabetes drug shows promise against rectal cancer in new trial

NCT ID NCT02437656

Completed Disease control Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether adding metformin, a common diabetes medicine, to standard chemo and radiation therapy could help people with locally advanced rectal cancer. 60 adults with stage T3 or T4 rectal cancer took part. The main goal was to see if the combination led to a complete disappearance of cancer cells in the tumor after surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rectal cancer rectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECTAL CANCER

Contacts and locations

Locations

Centre Galilée - Hôpital Privé La Louvière

Lille, 59045, France
Centre Gray

Maubeuge, 59600, France
Centre Hospitalier

Lens, 62300, France
Centre Joliot-Curie

Saint-Martin-Boulogne, 62200, France
Centre Léonard de Vinci - SARL du pont Saint Vaast

Douai, 59500, France
Centre Marie Curie

Arras, 62000, France
Centre Oscar Lambret

Lille, 59020, France
Centre Pierre Curie

Beuvry, 62880, France
Clinique des Dentellières

Valenciennes, 59300, France
Clinique du Bois - Centre Bourgogne

Lille, 59000, France
Institut André Dutreix

Dunkirk, 59240, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.